National Medical Products Administration (NMPA)
Is Exenatide legal in China?
Generics availableApproved, with a domestic generic approved in 2025; insurance covers it for type 2 diabetes.
Approved generic versions are sold.
Exenatide injection, the original AstraZeneca product, remains registered in China (import re-registration filed in 2023). On 2025-07-01 Chengdu Shengnuo Biotechnology (圣诺生物) announced that NMPA had issued a registration certificate for its domestic generic exenatide injection, for improving blood-sugar control in type 2 diabetes. The 2025 national insurance list includes exenatide injection for type 2 diabetes only.
Last verified 2026-09-29 · how we verify
Exenatide elsewhere
Sources (3)
- 01Chengdu Shengnuo Biotechnology: exenatide injection obtains drug registration certificate (圣诺生物关于自愿披露艾塞那肽注射液获得药品注册证书的公告)Chengdu Shengnuo Biotechnology (圣诺生物; Shanghai Stock Exchange STAR Market filing) · 2025-07-01 · accessed 2026-09-29
- 02National Basic Medical Insurance, Maternity Insurance and Work-Related Injury Insurance Drug List (2025 edition), effective 2026-01-01National Healthcare Security Administration (NHSA) · 2025-12 · accessed 2026-09-29
- 03CDE public register of accepted drug applications (受理品种目录浏览)Center for Drug Evaluation (CDE), NMPA · 2026-09-29 · accessed 2026-09-29